Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 9/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510779 | 0.90 | LMNA (0.60) | LMNAMAPTALDH1A1EGFRTP53 | |
| SCHEMBL12262268 | 0.85 | EGFR (0.68) | EGFRERBB2ERBB4JAK3RAB9A | |
| SCHEMBL13857448 | 0.82 | EGFR (0.67) | LMNAMAPTALDH1A1EGFRERBB2 | |
| SCHEMBL689431 | 0.81 | EGFR (0.55) | MAPTALDH1A1EGFRERBB2ERBB3 | |
| SCHEMBL7845264 | 0.77 | EGFR (0.47) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL15752411 | 0.76 | CDK4 (0.50) | LMNAMAPTALDH1A1EGFRJAK3 | |
| SCHEMBL12262262 | 0.76 | EGFR (0.65) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL7853506 | 0.76 | EGFR (0.46) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL690311 | 0.76 | MEN1 (0.49) | LMNAMAPTALDH1A1EGFRTP53 | |
| SCHEMBL7853525 | 0.76 | MCHR1 (0.47) | EGFRERBB2ERBB4JAK3ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | LMNA 2409/4885MAPT 1888/4885ALDH1A1 684/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | LMNA 2409/4885MAPT 1888/4885ALDH1A1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.